Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(AstraZeneca) D910DC00001 / EMERALD-2A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation.Meyers, Dr BrandonOpen to recruitmentNCT03847428
(CCTG) CRC.9 / NRG-GI005Phase II/III Study of Circulating tumOr DNA as a Predictive BiomarRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)Meyers, Dr BrandonOpen to recruitmentNCT04068103
(Merck) MK-3475-966Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with advanced/Unresectable Biliary Tract CarcinomaKazemi, Dr GhazalehOpen to recruitmentNCT04003636
(CCTG) CO.21 / CHALLENGEA Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients With High Risk Stage II or Stage III Colon Cancer: A Randomized Controlled Trial (CHALLENGE)Goffin, Dr JohnRecruitment on hold - COVID-19NCT00819208
Download PDF